International Workshop on HIV and Women 10 – 11 January 2011 , Washington Introduction : what took so long ?

[1]  E. Thiel,et al.  Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. , 2011, Blood.

[2]  G. Schoolnik,et al.  A multistage tuberculosis vaccine that confers efficient protection before and after exposure , 2011, Nature Medicine.

[3]  N. Ford,et al.  Distribution of Antiretroviral Treatment Through Self-Forming Groups of Patients in Tete Province, Mozambique , 2011, Journal of acquired immune deficiency syndromes.

[4]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[5]  Uwe Albrecht,et al.  Short-Term Monotherapy in HIV-Infected Patients with a Virus Entry Inhibitor Against the gp41 Fusion Peptide , 2010, Science Translational Medicine.

[6]  P. Kaleebu,et al.  Virological findings from the SARA trial: boosted PI monotherapy as maintenance second-line ART in Africa , 2010, Journal of the International AIDS Society.

[7]  M. Zolfo,et al.  Time for "test and treat" in prevention of mother-to-child transmission programs in low- and middle-income countries. , 2010, Journal of acquired immune deficiency syndromes.

[8]  C. Kankasa,et al.  Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Lynn Morris,et al.  Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.

[10]  R. Chaisson,et al.  Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa , 2010, AIDS.

[11]  R. Wood,et al.  Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial , 2010, The Lancet.

[12]  N. Ford,et al.  Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts , 2010, AIDS.

[13]  T. Hallett,et al.  A Decline in New HIV Infections in South Africa: Estimating HIV Incidence from Three National HIV Surveys in 2002, 2005 and 2008 , 2010, PloS one.

[14]  J. Krieger,et al.  The protective effect of adult male circumcision against HIV acquisition is sustained for at least 54 months: results from the Kisumu, Kenya trial , 2010 .

[15]  Gavin Churchyard,et al.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis. , 2009, The New England journal of medicine.

[16]  E. Thiel,et al.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. , 2009, The New England journal of medicine.

[17]  E. Lagarde,et al.  High rate of adverse events following circumcision of young male adults with the Tara KLamp technique: a randomised trial in South Africa. , 2009, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[18]  P. Hopewell,et al.  Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. , 2008, The Lancet. Infectious diseases.

[19]  M. Delaney.  Update from CROI 2008--stem cells: progress towards "the cure"? , 2008, Project Inform perspective.

[20]  Emmanuel Lagarde,et al.  Randomized, Controlled Intervention Trial of Male Circumcision for Reduction of HIV Infection Risk: The ANRS 1265 Trial , 2005, PLoS medicine.

[21]  C. van der Werken,et al.  Religious circumcision under local anaesthesia with a new disposable clamp , 2001, BJU international.

[22]  C. van der Werken,et al.  Results of Group-Circumcision of Muslim Boys in Malaysia with a New Type of Disposable Clamp , 2001, Tropical doctor.